Atropine drops: the alternative to the patch

The hardest part of patching is usually the patch itself: the child resists, the skin gets sore, classmates notice. Atropine drops aim at the same target without anything on the face.

This article covers how atropine works, how it compares with patching, and what it means in daily life. Whether to use it, and how often, is a decision for your eye doctor alone.

Atropine temporarily switches off the focusing muscle in the eye it is placed in. The result is that this eye can no longer see close objects sharply: books, worksheets and playing cards all go soft.

The drop goes in the strong eye. During near work its image is blurred, so the brain turns to what the weaker eye is sending. The logic matches patching exactly; only the tool differs, a medicine instead of a piece of fabric.

The effect is measured in days rather than hours. That is why atropine is usually not a daily routine but a dose at intervals your doctor sets, often once or twice a week.

This was tested head to head in a large randomised trial. 419 children under 7 with moderate amblyopia were assigned to either patching or atropine. At six months the gain in acuity was 3.16 lines with patching and 2.84 lines with atropine, a difference judged clinically inconsequential (Pediatric Eye Disease Investigator Group, Archives of Ophthalmology, 2002).

In the same trial, 79% of the patching group and 74% of the atropine group met the study's success criterion. Atropine is therefore not a fallback for when patching fails. It is a legitimate starting treatment in its own right.

The treated eye's pupil widens and becomes more sensitive to light. A hat and sunglasses make bright days easier.

The near blur lasts several days. Reading and writing tasks may go slower during that time, so it helps if the teacher knows what is going on.

Occasionally there are wider effects such as facial flushing, fever, a dry mouth or a fast pulse. If any of these appear, speak to your doctor before giving the next dose.

One more thing gets watched: reverse amblyopia, a drop in the previously strong eye. It is uncommon and shows up at routine checks, which is the real reason follow-up appointments matter.

Atropine's strongest card is adherence. One drop goes in and no negotiation runs for the rest of the day. For a family arguing over a patch every morning, that alone can decide the matter.

That advantage carries more weight than it looks. When patching is measured with dose monitors, children prescribed 6 hours a day received a mean of 4.2 hours, and those prescribed 12 hours received 6.2 (Stewart et al., BMJ, 2007). A good part of the difference between methods is therefore explained not by efficacy but by what can actually be carried out.

Visibility counts too. A child with nothing on their face does not stand out in class, and for school-age children that makes treatment easier to keep up.

The trade-off is control. The drop keeps the strong eye blurred at near for days and cannot be undone on demand. You can take a patch off; you cannot take a drop out. Which approach fits your child depends on the refractive error and the depth of the amblyopia, and that call belongs to your doctor.

Patching and atropine belong to the same family: both work by deliberately handicapping the strong eye so the weaker one is used. That approach is effective at raising acuity, but by definition it trains one eye at a time.

Dichoptic training takes a different route: both eyes work at once on complementary images, so depth and teamwork are part of the target rather than a hoped-for side effect. Neither is the rival of the other, and which path, or which order, suits your child is your doctor's call.